Trastuzumab gets the go ahead on both sides of the world

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.511, 2006-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Golimumab gets ready to go in rheumatoid arthritis

Inpharma, Vol. 1, Iss. 1521, 2006-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Monoclonal antibodies get the go-ahead in Japan

Inpharma, Vol. 1, Iss. 1635, 2008-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Trastuzumab modulates the effects of both pro- and anti-angiogenic factors

Inpharma, Vol. 1, Iss. 1333, 2002-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

R-FC cost effective for CLL on both sides of Atlantic

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 572, 2009-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

NIAID decides not to go ahead with PAVE 100 HIV vaccine trial

Inpharma, Vol. 1, Iss. 1648, 2008-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite